Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice

By afschroeder • December 16, 2025

Esposito AJ, Selvan KC, Richardson C, Khanna D, Bemiss BC, Bernstein EJ, Chung JH, Cox CW, Dematte JE, Denton CP, Distler O, Hinchcliff ME, Smith V, Strek ME, Varga J, Hoffmann-Vold AM, Volkmann ER. Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice. Chest. 2025 Dec 13:S0012-3692(25)05842-8. doi: 10.1016/j.chest.2025.11.047. Epub ahead of print. PMID: 41397518.

Tags: guidelines, interstitial lung disease, Publications, Rheumatology, screening, systemic sclerosis, Treatment

Pregnancy in Autosomal Dominant Polycystic Kidney Disease: Maternal and Fetal Considerations: A Narrative Review

Sarmadian PJ, Pirooz AD, Al Baghdadi M, Kamgar M, Afshar Y, Nobakht N. Pregnancy in Autosomal Dominant Polycystic Kidney Disease: Maternal and Fetal Considerations: A[...]

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

Mease PJ, Chandran V, Armstrong AW, Blanco R, Ogdie A, Siegel EL, Gottlieb AB, Zeng X, Thaçi D, Kishimoto M, Schulze-Koops H, Kivitz A, Dokoupilová[...]

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]